RCUS

Company Overview — What Does Arcus Biosciences, Inc. Do?

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences, Inc. (RCUS) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Terry J. Rosen and employs approximately 500 people. With a market capitalization of $2.7B, RCUS is one of the notable companies in the Healthcare sector.

Arcus Biosciences, Inc. (RCUS) Stock Rating — Hold (April 2026)

As of April 2026, Arcus Biosciences, Inc. receives a Hold rating with a composite score of 35.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.RCUS ranks #1,707 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Arcus Biosciences, Inc. ranks #166 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RCUS Stock Price and 52-Week Range

Arcus Biosciences, Inc. (RCUS) currently trades at $22.34. The stock lost $0.94 (4.0%) in the most recent trading session. The 52-week high for RCUS is $26.40, which means the stock is currently trading -15.4% from its annual peak. The 52-week low is $6.50, putting the stock 243.7% above its annual trough. Recent trading volume was 591K shares, suggesting relatively thin trading activity.

Is RCUS Overvalued or Undervalued? — Valuation Analysis

Arcus Biosciences, Inc. (RCUS) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.38x, versus the sector average of 2.75x. The price-to-sales ratio is 10.56x, compared to 1.66x for the average Healthcare stock.

At current multiples, Arcus Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Arcus Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Arcus Biosciences, Inc. (RCUS) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -53.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -29.8% versus the sector average of -33.1%.

On a margin basis, Arcus Biosciences, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -301.4% (sector: -66.1%). Net profit margin stands at -277.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -33.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RCUS Debt, Balance Sheet, and Financial Health

Arcus Biosciences, Inc. has a debt-to-equity ratio of 16.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.36x, indicating strong short-term liquidity. Total debt on the balance sheet is $99M. Cash and equivalents stand at $238M.

RCUS has a beta of 1.45, meaning it is more volatile than the broader market — a $10,000 investment in RCUS would be expected to move 44.9% more than the S&P 500 on any given day. The stability factor score for Arcus Biosciences, Inc. is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Arcus Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Arcus Biosciences, Inc. reported revenue of $262M and earnings per share (EPS) of $-3.29. Net income for the quarter was $-339M. Gross margin was 100.0%. Operating income came in at $-377M.

In FY 2025, Arcus Biosciences, Inc. reported revenue of $247M and earnings per share (EPS) of $-3.29. Net income for the quarter was $-353M. Revenue grew -4.3% year-over-year compared to FY 2024. Operating income came in at $-386M.

In Q3 2025, Arcus Biosciences, Inc. reported revenue of $26M and earnings per share (EPS) of $-1.27. Net income for the quarter was $-135M. Revenue grew -45.8% year-over-year compared to Q3 2024. Operating income came in at $-142M.

In Q2 2025, Arcus Biosciences, Inc. reported revenue of $160M and earnings per share (EPS) of $0.00. Net income for the quarter was $0. Revenue grew 310.3% year-over-year compared to Q2 2024. Operating income came in at $-8M.

Over the past 8 quarters, Arcus Biosciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $39M to $262M. Investors analyzing RCUS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RCUS Dividend Yield and Income Analysis

Arcus Biosciences, Inc. (RCUS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RCUS Momentum and Technical Analysis Profile

Arcus Biosciences, Inc. (RCUS) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RCUS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Arcus Biosciences, Inc. (RCUS) ranks #166 out of 838 stocks based on the Blank Capital composite score. This places RCUS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RCUS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RCUS vs S&P 500 (SPY) comparison to assess how Arcus Biosciences, Inc. stacks up against the broader market across all factor dimensions.

RCUS Next Earnings Date

No upcoming earnings date has been announced for Arcus Biosciences, Inc. (RCUS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RCUS? — Investment Thesis Summary

Arcus Biosciences, Inc. presents a balanced picture with arguments on both sides. The quality score of 24/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 38/100) increases portfolio risk.

In summary, Arcus Biosciences, Inc. (RCUS) earns a Hold rating with a composite score of 35.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RCUS stock.

Related Resources for RCUS Investors

Explore more research and tools: RCUS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RCUS head-to-head with peers: RCUS vs AZN, RCUS vs SLGL, RCUS vs VMD.